The U.S. Food and Drug Administration (FDA) approved Phesgo on June 29, 2020, for the treatment of HER2-positive breast cancer.

The U.S. Food and Drug Administration (FDA) approved fenfluramine on June 25, 2020, for the treatment of seizures associated with Dravet syndrome in patients two years of age and older.

The U.S. Food and Drug Administration (FDA) granted accelerated approval to lurbinectedin on June 15, 2020.

The U.S. Food and Drug Administration (FDA) approved inebilizumab on June 11, 2020.

The U.S. Food and Drug Administration (FDA) approved Oriahnn on May 29, 2020.

The U.S. Food and Drug Administration (FDA) approved Tauvid on May 28, 2020.

The U.S. Food and Drug Administration (FDA) approved Phexxi on May 22, 2020.

Cerianna (fluoroestradiol F 18) is FDA approved. The U.S. Food and Drug Administration (FDA) approved Cerianna on May 20, 2020.

The U.S. Food and Drug Administration (FDA) approved Ripretinib on May 15, 2020, for the treatment of advanced gastrointestinal stromal tumor (GIST) in adult patients who have received prior treatment with three or more kinase inhibitors, including imatinib.

The U.S. Food and Drug Administration (FDA) approved Selpercatinib on May 8, 2020, under an accelerated approval process.

The FDA granted approval for capmatinib on May 6, 2020. Capmatinib is used to treat non-small cell lung cancer (NSCLC) that has spread to other parts of the body (metastatic) or cannot be removed with surgery.

The FDA approved Darzalex Faspro for the treatment of multiple myeloma and light chain amyloidosis in adults on May 1, 2020.